Factors Associated with Arterial Stiffness in Chronic Hemodialysis Patients in Jakarta: The Role of Hemodialysis Frequency and Pentraxin 3
Keywords:
arterial stiffness, pulse wave velocity, pentraxin 3, hemodialysis frequencyAbstract
Background: arterial stiffness is a mortality predictor in hemodialysis patients, hemodialysis induces inflammation, marked by an intradialysis increase in the inflammatory marker pentraxin 3 (PTX3). Arterial stiffness in twice-weekly hemodialysis patients in Indonesia is lower than has been found in studies of thrice-weekly patients. This study therefore aims to determine the factors associated with arterial stiffness, focusing on the role of hemodialysis frequency and PTX3. Methods: a cross-sectional study was conducted at Cipto Mangunkusumo Hospital, Fatmawati Hospital, and Medistra Hospital involving patients with twice- and thrice-weekly hemodialysis. Arterial stiffness was measured by carotid-femoral pulse wave velocity after hemodialysis, and blood samples for PTX3 testing were taken before hemodialysis. Bivariate and multivariate analyses were performed using chi-squared tests and logistic regression. Results: out of 122 subjects, 82 underwent twice-weekly hemodialysis. There was no difference in arterial stiffness between patients with twice- and thrice-weekly hemodialysis. In bivariate analysis, PTX3, cardiovascular disease, dialysis vintage had p values of <0.05, while the subsequent multivariate analysis showed that PTX3>2.3 ng/ml was associated with arterial stiffness (adjusted OR 5.18; 95% CI 1.07–24.91), as well as cardiovascular disease (adjusted OR 3.67; 95% CI 1.40–10.55), LDL (adjusted OR 3.10; 95% CI 1.04–9.24), and dialysis vintage (adjusted OR 2.72; 95% CI 1.001–7.38). Conclusion: predialysis PTX3 levels above 2.3 ng/ml were associated with arterial stiffness. There was no difference in arterial stiffness between patients with twice- and thrice-weekly hemodialysis.References
Perhimpunan Nephrologi Indonesia. 11th report of Indonesian Renal Registry 2018. Jakarta: Pernefri; 2019.
Georgianos PI, Pikilidou MI, Liakopoulos V, Balaskas E V, Zebekakis PE. Arterial stiffness in end-stage renal disease—pathogenesis, clinical epidemiology, and therapeutic potentials. Hypertens Res. 2018;41(5):309–19.
Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR. Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 2019;32(1):58–71.
Williams B, Mancia G, Spiering Wi, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Eur Heart J. 2018;39:3021–104.
Canaud B, Cristol J, Morena M, Moragues H, Vaussenat F, Bosc J. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 1999;17:99–106.
Nguyen A, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int. 1985;28:158–67.
Galli F, Canestrari F, Bellomo G. Pathophysiology of the oxidative stress and its implication in uremia and dialysis. Contrib Nephrol. 1999;127:1–31.
Lakshmi BS, Devi NH, Suchitra MM, Rao PVLNS, Kumar VS. Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease. Ren Fail. 2018;40(1):531–40.
Oglio M, Simone S, Ciccone M, et al. Neutrophil-dependent pentraxin-3 and reactive oxygen species production modulate endothelial dysfunction in haemodialysis patients. Nephrol Dial Transp. 2017;32(9):1540–9.
Xu Y, Ding X, Zou J, et al. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients. Ren Fail. 2011;33(10):998–1004.
Krzanowski M, Krzanowska K, Gajda M, et al. Pentraxin 3 as a new indicator of cardiovascular related death in patients with advanced chronic kidney disease. Polish Arch Intern Med. 2017;127(3):170–7.
KDOQI. Clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis. 2006;48:S1–322.
Sari CMY, Nainggolan G, Marbun M. Correlation between central arterial stiffness and handgrip strength in chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2019;30:891–7.
Utescu MS, Couture V, Mac-way F, et al. Determinants of progression of aortic stiffness in hemodialysis patients: a prospective longitudinal study. Hypertension. 2013;62:154–60.
Krishnasamy R, Tan S, Hawley CM, et al. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrol. 2017;18(1):281.
Wang M, Tsai W, Chen J, Huang J. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005;45(3):494–501.
El Sebai AA, El Hadidi ES, Abdel Al H, El Sayed EY. Pentraxin-3 in hemodialysis patients: relationship to comorbidities. Saudi J Kidney Dis Transpl. 2016;27(4):701–9.
Suliman M, Qureshi A, Carrero J, et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. Q J Med. 2008;101:397–405.
Sjöberg B, Snaedal S, Stenvinkel P, Qureshi AR, Heimbürger O, Bárány P. Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients. Clin Kidney J. 2014;7:373–9.
London GM, Safar ME, Pannier B. Aortic aging in ESRD: structural, hemodynamic, and mortality implications. J Am Soc Nephrol. 2016;27:1837–46.
Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99(18):2434–9.
Shoji T, Emoto M, Shinohara K, Kakiya R, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol. 2001;12:2117–24.
Verbeke F, Van Biesen W, Honkanen E. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the Calcification Outcome in Renal Disease (CORD) Study. Clin J Am Soc Nephrol. 2011;6:153–9.
Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Atherosclerosis and lipoproteins rapid communication production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arter Thromb Vasc Biol. 2002;22:e10–4.
Goldsmith D, Covic A, Sambrook P, Ackrill P. Vascular calcification in long-term haemodialysis patient in a single unit: a retrospective analysis. Nephron. 1997;77:37–43.
Aviram M. Hyperlipidaemia and cardiovascular disease: inflammation and oxidative stress in diabetic patients. Curr Opin Lipidol. 2009;20:258–9.
Mikael LDR, Machado A, De Paiva G, et al. Vascular aging and arterial stiffness. Arq Bras Cardiol. 2017;109(3):253–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
